Compare HOVR & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | ICCC |
|---|---|---|
| Founded | 2013 | 1982 |
| Country | Canada | United States |
| Employees | 30 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.6M | 75.8M |
| IPO Year | N/A | 1995 |
| Metric | HOVR | ICCC |
|---|---|---|
| Price | $2.22 | $9.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.33 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 19.6K |
| Earning Date | 04-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $44.71 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $1.16 | $4.52 |
| 52 Week High | $4.18 | $10.75 |
| Indicator | HOVR | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 47.96 |
| Support Level | $2.06 | $9.29 |
| Resistance Level | $2.56 | $10.75 |
| Average True Range (ATR) | 0.20 | 0.38 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 19.48 | 6.78 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.